Background: Continued monitoring and reporting of outcomes in clubfoot patients are important for providing an indicator of functional outcomes and surveillance and treatment for problems or recurrences. The purpose of this study is to report the 5-year outcomes of the updated cohort of 44 patients with 65 idiopathic clubfeet treated with manipulation, casting, and Botulinum toxin A (BTX-A).
Methods: As part of the original study, the patients underwent the corrective treatment phase of manipulation and casting followed with BTX-A injection and then the maintenance phase of bracing. The patients were seen at regular intervals and a detailed clinical history was maintained for each patient including ankle range of motion, recurrences, and interventions for recurrences.
Results: Mean values for range of motion at the 5-year visit were 22.3 and 17.1 degrees for dorsiflexion with the knee in flexion and extension, respectively. Overall, 48% (31 of 65 clubfeet) successfully responded to a single BTX-A injection and experienced no recurrence over the follow-up period. At least 1 repeat BTX-A injection was required in 34 clubfeet, for an overall recurrence rate of 52%. Surgery was required in 10 clubfeet, and the overall surgical rate was 15.4%.
Conclusions: Idiopathic clubfeet treated with BTX-A continued to show good outcomes at 2 to 5-year follow-up. The experience with this cohort provides support for the effectiveness of BTX-A in the initial correction and continued management of idiopathic clubfoot.
Level Of Evidence: Levels III to IV. This is a prospective, nonexperimental clinical study investigating efficacy of an innovative treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/BPO.0b013e3181b2b3d4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Contemporary Algorithm for Treating Bromhidrosis: A Review of Treatment Available.
Aesthetic Plast Surg
January 2025
Department of Plastic Surgery, The First Affiliated Hospital of Fujian Medical University, No. 20, Chazhong Road, Taijiang District, Fuzhou, China.
Bromhidrosis significantly impacts individuals' social, professional, and emotional well-being. Traditional treatments such as en bloc excision and alcohol injections are now less favored due to associated complications and suboptimal outcomes. Current evidence identifies botulinum toxin A (BTX-A) as the first-line treatment for mild to moderate cases (Grade 0-2), attributed to its high efficacy, excellent safety profile, and minimally invasive nature.
View Article and Find Full Text PDF[Safety and efficacy of Relatox in comparison with Dysport in the treatment of focal spasticity of the upper limb in patients after stroke and traumatic brain injury (results of a prospective simple blind randomized comparative study in parallel groups)].
Zh Nevrol Psikhiatr Im S S Korsakova
December 2024
GUTA-CLINIC LLC, Moscow, Russia.
Article Synopsis
- The study aimed to evaluate the safety and effectiveness of Relatox, a type of botulinum toxin, in treating focal spasticity of the upper limb caused by cerebrovascular accidents or traumatic brain injuries.
- It involved 210 patients divided into two groups; one received Relatox injections, while the other received Dysport. Both groups showed a reduction in spasticity over 12 weeks, with no significant differences between the two treatments.
- Various measurements were used to assess spasticity, disability, pain, and treatment satisfaction, and both medications were found to be effective, with a report on adverse events collected throughout the study.
Early effects of α7nAChR regulation on maxillary expansion in mice : A study on osteogenesis and inflammatory factors.
J Orofac Orthop
December 2024
Department of Orthodontics, Beijing Stomatological Hospital, Capital Medical University, 100050, Beijing, China.
Purpose: We aimed to investigate early effects of regulating alpha‑7 nicotinic acetylcholine receptor (α7nAChR) agonists and antagonists on maxillary expansion in mice.
Methods: We allocated 36 six-week-old male C57BL/6J mice into three group: 1) expansion alone, 2) expansion plus the α7nAChR-specific agonist 3‑(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride (GTS-21), and 3) expansion plus alpha-bungarotoxin (α-BTX), a competitive antagonist of α7nAChR. The groups were daily injected with saline, GTS-21 (4 mg/kg/day) or α‑BTX (1 mg/kg/day), respectively, from days 0-7.
Treatment with OnabotulinumtoxinA for Oromandibular Dystonia: A Systematic Review and Meta-Analysis.
Toxins (Basel)
December 2024
Department of Neurology, Tokushima University, Tokushima 770-8503, Japan.
Article Synopsis
- Oromandibular dystonia (OMD) is a condition causing muscle contractions in the jaw and related areas, and this study analyzed the effects of botulinum toxin (onabotulinumtoxinA) as a treatment.
- A meta-analysis of 26 studies with 1103 patients showed that 96.2% experienced a positive response to the injections, with 88.9% achieving significant improvement of over 50%.
- Although 17.8% of patients had adverse effects, mainly dysphagia (10.1%), the overall findings suggest that botulinum toxin is an effective treatment for OMD but further studies are needed for more conclusive results.
The Lack of Effect of Botulinum Toxin-A on Upper Limb Activity in Chronic Stroke: A Short Report from the InTENSE Trial.
Toxins (Basel)
November 2024
Alfred Health, Melbourne, VIC 3004, Australia.
Article Synopsis
- This study analyzed the effects of botulinum toxin-A on upper limb issues in chronic stroke survivors, focusing on those with significant spasticity.
- The research involved 71 stroke survivors and measured changes in various outcomes, including upper limb activity, spasticity, and grip strength, before and three months after treatment.
- Results showed no significant improvement in any of the measured outcomes, indicating that botulinum toxin-A may not be beneficial for improving upper limb function in this patient group with severe activity limitations.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!